AbbVie And Biogen Make ICER's Unsupported Price Increase List Three Years Running
Executive Summary
ICER's report on unsupported price increases highlighted seven drugs that cost the US health system $1.67bn due to price increases after rebates and other concessions.
You may also be interested in...
Costs From ICER’s Unsupported Price Increase List Tick Back Up
Humira topped ICER’s list of drugs with unsupported price increases that added the most cost to the US health care system during 2022, its last year before biosimilars hit the US market.
ICER: Antibodies For MS – Including TG’s – Need Big Price Cut For Cost-Effectiveness
The pricing watchdog said it found “insufficient evidence” to differentiate the benefit of TG’s ublituximab from other antibodies already on the market for multiple sclerosis.
Drugs From Bausch, J&J And Amgen Top ICER's Unsupported Price Increase List
Seven of the top 10 drugs with net price increases in 2021 that had a substantial effect on US spending did not have adequate new evidence to support any price increase, ICER determined.